Table 2.

Comparison of factors influencing the SVR rate in treated patients

Variable		Relapsers (n = 75)	Non-responders (n = 42)
Gender
	Male (n = 91)	61/63 (97)	27/28 (96)
	Female (n = 26)	12/12 (100)	14/14 (100)
	p-value	< 0.09	< 0.06
Age (years), n (%)
	30-50	48/49 (98)	27/27 (100)
	51-65	25/26 (96)	14/15 (93)
	p-value	< 0.06	< 0.05
Baseline HCV RNA (log10 IU/l), n (%)
	≤ 100,000 IU/ml	49/51 (96)	19/19 (100)
	≥ 100,000 IU/ml	24/24 (100)	22/23 (96)
	p-value	< 0.08	< 0.07
Fibrosis stages
	F1-F2	28/28 (100)	9/9 (100)
	F3-F4	45/47 (96)	32/33 (97)
	p-value	< 0.07	< 0.06
Undetectable HCV PCR, n (%)
	4 weeks	61/75 (81)	30/42 (71)
	24 weeks	12/75 (16)	11/42 (26)
	p-value	< 0.005	< 0.002
RBV dose, n (%)
	No dose modification	54/54 (100)	31/31 (100)
	Reduction in RBV dose	12/12 (100)	6/6 (100)
	Stop RBV	7/9 (78)	4/5 (80)
	p-value	< 0.003	< 0.005

SVR – sustained virological response, RVR – rapid virological response, RBV – ribavirin